NEW YORK (GenomeWeb News) – Atossa Genetics today disclosed it has been warned by the US Food and Drug Administration over its system for the analysis of nipple aspirate fluid.

In a document filed with the US Securities and Exchange Commission, Atossa said that it received a warning letter from FDA regarding the system called Mammary Aspirate Specimen Cytology Test System, or MASCT, on Feb. 21.

FDA alleges in its warning that after MASCT was cleared by FDA, Atossa made changes to the platform that requires submission of an additional 510(k) notification, Atossa said

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.